March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a reduction in blood sugar levels during a late-stage ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the ...

The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’  therapy for a rare form of obesity ​caused ...

Overall, the obesity rate among high schoolers rose from 13.7% in 2013 to 15.9% in 2023. While that might look like a small ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...

Obesity is a chronic disease that can significantly affect an individual’s overall health. In this Care Cues, experts discuss ...

Current childhood obesity prevention programs mostly focus on nutrition education and physical activity, which too often fail ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

Muscle mass increased or remained stable relative to body weight in middle-aged mice and humans on GLP-1 drugs.

A new Pediatrics study is putting a spotlight on something most parents don’t think about when it comes to kids’ health: ...

UK children are getting taller. The reason why reveals a troubling story about obesity, inequality and poverty.